



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 11

**Complete if Known**

Application Number	09/730,329
Filing Date	12/04/2000
First Named Inventor	John
Art Unit	1653
Examiner Name	Kam, C.
Attorney Docket Number	015270-006460US

**U.S. PATENT DOCUMENTS**

Examiner	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
CMK	9	6,211,428	04-03-2001	Singh et al.	
	10	6,162,630	12-19-2000	Powell et al.	
	11	6,025,180	02-15-2000	Powell et al.	
	13	5,877,015	03-02-1999	Hardy et al.	
	141	5,863,756	01-26-1999	Barr et al.	
	14	5,849,560	12-15-1998	Abraham	
	15	5,837,672	11-17-1998	Schenk et al.	
	16	5,795,963	08-18-1998	Mullan	
	17	5,766,846	06-16-1998	Schlossmacher et al.	
	18	5,750,349	05-12-1998	Suzuki et al.	
	19	5,744,346	04-28-1998	Chrysler et al.	
	20	5,733,768	03-31-1998	Dixon et al.	
	21	5,593,846	01-14-1997	Schenk et al.	
	22	5,455,169	10-03-1995	Mullan	
	23	5,424,205	06-13-1995	Dovey et al.	
	140	2004/0234976	11-25-2004	Gurney et al.	
	123	2004/0166507	08-26-2004	Gurney et al.	
	124	2004/0048303	03-11-2004	Gurney et al.	
	125	2004/0043408	03-04-2004	Gurney et al.	
	128	2002/0081634	06-27-2002	Gurney et al.	
	130	2002/0037315	03-28-2002	Gurney et al.	
	131	2001/0021391	09-13-2001	Gurney et al.	
	142	10/817,979	unavailable	Gurney et al.	
	143	10/477,076	unavailable	Gurney et al.	
	144	09/668,314	03-12-2002	Gurney et al.	
	94	09/548,370	05-09-2006	Gurney et al.	
CMK	97	09/548,369	unavailable	Gurney et al.	

Examiner  
Signature

CMK

Date  
Considered

12/2/05

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Applicant's unique citation designation number (optional). <sup>3</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231 60597020

CMK 10/27/08

CMK 10/27/08

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 11

**Complete if Known**

Application Number	09/730,329
Filing Date	12/04/2000
First Named Inventor	John
Art Unit	1653
Examiner Name	Kam, C.
Attorney Docket Number	015270-006460US

**U.S. PATENT DOCUMENTS**

Examiner	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
CMK	95	09/548,365	03-15-2005	Gurney et al	
	27	09/404,133	unavailable	Gurney et al.	
	28	09/277,229	unavailable	Citron et al.	
	29	60/210,292	unavailable	Hong et al.	
	30	60/178,368	unavailable	Lin et al.	
	31	60/177,836	unavailable	Lin et al.	
	152	60/169,232	unavailable	Gurney et al.	
	32	60/168,060	unavailable	Lin et al.	
	33	60/155,493	unavailable	Gurney et al.	
	34	60/141,363	unavailable	Lin et al.	
	35	60/139,172	unavailable	Anderson et al.	
	36	60/119,571	unavailable	Basi et al.	
	37	60/114,408	unavailable	Basi et al.	
CMK	38	60/101,594	unavailable	Gurney et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials <sup>5</sup>	Cite No. <sup>1</sup>	Country Code <sup>3</sup>	Foreign Patent Document Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
CMK	170	EP	1 445 263	A1	08-11-2004			
	171	EP	855 442	A2	07-29-1998			
	39	EP	855 444	A2	07-29-1998			
	40	EP	848 062	A2	06-17-1998			
	166	GB	2 364 059	B	01-14-2004			
	167	GB	2 389 114	B	02-04-2004			
	168	GB	2 389 113	B	02-04-2004			
	169	GB	2 389 182	B	02-04-2004			
CMK	134	WO	01/50829	A2	07-19-2001			

Examiner  
SignatureDate  
Considered

12/5/05

<sup>5</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231 60597020

CMK

10/27/07

CMK

10/27/08



Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/730,329
				Filing Date	12/04/2000
				First Named Inventor	John
				Art Unit	1653
				Examiner Name	Kam, C.
Sheet	6	of	11	Attorney Docket Number	015270-006460US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
CMK	104	BALDWIN et al., "Crystal structures of native and inhibited forms of human cathepsin D: Implications for lysosomal targeting and drug design," <u>PNAS</u> , 90:6796-6800 (1993).		
	181	BORK, P., "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle," <u>Genome Research</u> , 10:398-400 (2000).		
	179	BROUN et al., "Catalytic Plasticity of Fatty Acid Modification Enzymes Underlying Chemical Diversity," <u>Science</u> , 282:131-133 (1998).		
	105	BROWN et al., "Evaluation of Cathepsins D and G and EC 3.4.24.15 as Candidate $\beta$ -Secretase Proteases Using Peptide and Amyloid Precursor Protein Substrates," <u>Journal of Neurochemistry</u> , 66:2436-2445 (1996).		
	106	CHEVALLIER et al., "Cathepsin D displays in vitro $\beta$ -secretase-like specificity," <u>Brain Research</u> , 750:11-19 (1997).		
	64	CHYUNG et al., "Novel $\beta$ -Secretase Cleavage of $\beta$ -Amyloid Precursor Protein in the Endoplasmic Reticulum/Intermediate Compartment of NT2N Cells," <u>Journal of Cell Biology</u> , 138:671-680 (1997).		
	178	DAS et al., "Estrogenic responses in estrogen receptor- $\alpha$ deficient mice reveal a distinct estrogen signaling pathway," <u>PNAS</u> , 94:12786-12791 (1997).		
CMK 10/27/08	151	Declaration of Michael Bienkowski, Ph.D. in U.S. patent application 09/548,368 (2001)		
	183	DENNIS et al., "Kunitz Domain Inhibitors of Tissue Factor-Factor VIIa," <u>J. Biol. Chem.</u> , 269(35):22129-22136 (1994).		
	107	DIEDRICH et al., "Nucleotide sequence of a cDNA encoding mouse cathepsin D," <u>Nucleic Acids Research</u> , 18:7184 (1990).		
	65	Elan Corporation, plc and Pharmacia Corporation announce research collaboration, News 08/09/2000, www.elancorp.com.		
CMK	155	Examination Report for United Kingdom Application 00121314.9 dated November 1, 2002.		

Examiner Signature		Date Considered	12/2/05
--------------------	--	-----------------	---------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60597020



Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/730,329
				Filing Date	12/04/2000
				First Named Inventor	John
				Art Unit	1653
				Examiner Name	Kam, C.
Sheet	9	of	11	Attorney Docket Number	015270-006460US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
CMK	173	KRISTIE, T. M., "The Mouse Homologue of the Human Transcription Factor C1 (Host Cell Factor)," <u>J. Biol. Chem.</u> , 272(42):26749-26755 (1997).		
	187	KUNTZ, I. D., "Structure-Based Strategies for Drug Design and Discovery," <u>Science</u> , 257:1078-1082 (1992).		
	174	Li et al., "Cloning and Characterization of Three New Murine Genes Encoding Short Homologues of RNase P RNA*," <u>J. Biol. Chem.</u> , 270(42):25281-25285 (1995).		
	108	MAJER et al., "Structure-based subsite specificity mapping of human cathepsin D using statine-based inhibitors," <u>Protein Science</u> , 6:1458-1466 (1997).		
	76	MULLAN et al., "A Pathogenic Mutation for Probable Alzheimer's Disease in the APP Gene at the N-Terminus of $\beta$ -Amyloid," <u>Nature Genetics</u> , 1: 345-347 (1992).		
	150	Office Action dated 5/6/02 in U.S. patent application 09/548,368 (2002)		
	77	PCT Search report for PCT/US99/20881 (2000)		
	78	PCT Search report for PCT/US00/03819 (2002)		
	79	PONTE et al., "A New A4 Amyloid mRNA Contains a Domain Homologous to Serine Proteinase Inhibitors," <u>Nature</u> , 331:525-527 (1988).		
	177	RAABE et al., "Knockout of the abetalipoproteinemia gene in mice: Reduced lipoprotein secretion in heterozygotes and embryonic lethality in homozygotes," <u>PNAS</u> , 95:8686-8691 (1998).		
	109	SAFTIG et al., "Amyloidogenic Processing of Human Amyloid Precursor Protein in Hippocampal Neurons Devoid of Cathepsin D," <u>Journal of Biological Chemistry</u> , 271:27241-27244 (1996).		
	110	SCHECHTER et al., "On the size of the active site in proteases. I. Papain," <u>Biochemical and Biophysical Research Communications</u> , 27:157-162 (1967).		
CMK	80	SEUBERT et al., "Secretion of $\beta$ -amyloid Precursor Protein Cleaved at the Amino Terminus of the $\beta$ -amyloid Peptide," <u>Nature</u> , 361:260-263 (1993).		
Examiner Signature			Date Considered	12/2/05

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60597020